Bernstein estimates that OpenAI’s infrastructure spending through 2030 will total 614 billion dollars if all contracts are delivered on time and none are canceled; whether revenue can continue to grow rapidly will affect its ability to pay and suppliers’ long-term demand.
Apple’s fiscal 2026 fourth-quarter revenue and earnings per share both beat expectations, and its revenue guidance for the December quarter also exceeded consensus. However, rising memory prices and slower services growth are weighing on gross margins, prompting Bernstein to raise its revenue forecasts while cutting its earnings forecasts.
Faster adoption of in-house CPUs at Amazon and Google has prompted Bernstein to raise its forecasts for TSMC's advanced process technologies and earnings; weakness in low-end devices and the costs of new process technologies and overseas production constrain margins.
First-quarter revenue for fiscal 2027 reached $19.95 billion, exceeding the company's preliminary range. The midpoint of next-quarter revenue guidance was 24% above market consensus, but gross margin fell quarter over quarter and free cash flow remained negative.
Falling bond yields helped European real estate stocks outperform the market in October. Bernstein sees valuations as attractive relative to history, but operating and asset price trends differ across retail properties, prime offices and German residential assets.
North American hotel performance drove growth in Marriott’s global revenue per available room, and incentive management fees exceeded expectations; the company also raised its full-year earnings and capital return guidance.
Incyte’s third-quarter revenue rose 14% year over year, with Opzelura driving a beat against the revenue consensus. The company discontinued a phase III ovarian cancer trial; Bernstein supports the decision but remains on the sidelines.
Newport News drove HII’s third-quarter revenue and earnings per share above consensus, and the company raised its full-year shipbuilding revenue guidance; Ingalls output and margins continue to constrain overall improvement.
Business jet deliveries and shipbuilding output helped third-quarter results exceed consensus. Bernstein raised its earnings forecasts and target price, while noting that capacity, supply chains and the transition to new land combat equipment continue to constrain growth.
Asia-Pacific and fragrance drove organic sales growth of 6% in the first quarter, while adjusted operating margin rose to 12.1%. The company raised its full-year guidance, but the outlook still implies a weaker second half.
The company raised its 2026 revenue guidance, but the expiry of Eliquis’s European patent will create pressure. Bernstein believes clinical results for Milvexian and Cobenfy will shape the handover to future growth.
Apple’s revenue rose 12% year over year in the fourth quarter of fiscal 2026, but gross margin guidance for the December quarter was below market consensus. Bernstein believes rising memory costs will continue to squeeze margins, while remaining optimistic about Apple’s long-term opportunity in on-device intelligence.
Bernstein estimates that, assuming modest revenue growth and achievement of two cost-reduction targets, buyers could pay a premium of 20%–30% over the pre-report share price; retaining low-interest debt and raising equity financing are key.
Prediction market trading volumes are growing rapidly, but growth in sports betting and online gaming is slowing. Bernstein sees promise in fees and market-making revenue, while cutting its price targets for both companies.
In monitored US channels, private-label volume share rose year over year in the past 12 weeks, while value share still declined slightly. Bernstein believes retailers may be widening the price gap between private labels and national brands; chocolate and coffee gained share, while some snack categories moved in the opposite direction.
In the week ended 23 October, US GLP-1 prescriptions rose 2.7% week over week, with Zepbound contributing the largest increase; among new-to-brand prescriptions for oral drugs, Wegovy Pill grew faster than Foundayo.
Membership exceeded Bernstein’s expectations in the third quarter of 2026, and average membership density per club continued to rise; however, full-year club opening guidance remained unchanged, and some additions came from rebranding existing clubs.
Global semiconductor sales rose 10.8% month over month in September, above the historical average for the period; year-over-year growth slowed from 158% in August to 151%. Memory prices accounted for most industry growth since the start of the year, but performance varied across products and end markets.
Growth in Japanese machine tool orders from China slowed in September, while North American orders continued to accelerate; industrial robot exports and automation component production data show that the overseas recovery is not strengthening in every segment at the same pace.
Bernstein expects new supply to exceed demand, and further drawdowns of high inventories could put additional pressure on iron ore prices; higher freight rates raise marginal costs and support prices.